A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
about
Nedaplatin: a cisplatin derivative in cancer chemotherapyProspective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study.Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma.Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancerSecond-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma.BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal CarcinomaThe role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible?Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancerCapecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.Second-line therapy for esophageal cancer.New and emerging combination therapies for esophageal cancer.A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives.Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.Immunotherapy for Esophageal Squamous Cell Carcinoma.Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Treatment options for esophageal squamous cell carcinoma.Emerging tyrosine kinase inhibitors for esophageal cancer.Emerging mAbs for the treatment of esophagogastric cancer.Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma.Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane.The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality TherapyCurrent management of esophageal squamous-cell carcinoma in Japan and other countries.Esophageal cancer chemotherapy: recent advances.Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model.A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
P2860
Q24623561-56748FA4-8075-4E2F-A127-B1A8B3B67C53Q30907567-1C423A50-0F5A-4D1D-B468-BA126292FDC2Q33591847-CAC24F75-0072-4992-84AF-F7E5A94A3589Q34056960-0288AC09-6779-4430-B5C4-5CB06D9C6EB5Q34098746-BD39E1AD-2A8E-489C-A6B5-6698C9DA0DABQ34334545-F6E6CF7A-0AFD-4E41-A3D2-C7E5DF0C923CQ34348291-01ECCA42-759B-4912-A846-ED8C1DCAD453Q34388021-409E2D5F-1279-44DE-BCA3-B4EC1698CA2BQ34550974-F0F0341B-AD98-4B23-97EF-3145C586AE83Q35375610-38CC968A-2E27-49BE-8140-99CBBC16D80DQ36104323-4E81A42C-8986-4F61-BB73-84E6D634FB66Q36303967-BA6EF791-8AE2-4BB2-8E03-52DEA189602AQ36376439-5F06A697-31ED-4D25-B45B-1B5193CCB07DQ36609800-8B354F7F-9953-47D4-87FC-A282F26E50B5Q36616002-808C6D1B-4DD6-4D95-A37B-6C7287507796Q36661984-AD44F45E-32D5-41A0-91E1-AA8C2061A07AQ36842786-99AA5DB7-2ABF-46B3-9AAA-AC007D8E5B8AQ36996728-6556DA22-E3F1-43B9-9AE1-A3C8D27BFF8FQ37038184-FAFDB2B7-947E-4091-8FB3-268A1709AD29Q37193049-96262D12-6315-48D0-8EA2-FB8382DF1171Q37198610-FD19F788-8A7C-421B-8969-08A5611B9352Q37618803-D7B0EB13-502C-4E02-894D-9D2F3B409669Q37730966-B6E1580E-06B1-4519-BB1C-910C2619E279Q37957744-6B926A1A-1861-42EE-B2E0-E0285A9833AAQ38107007-262E622E-6353-4F5B-8748-6E7D940ECAF2Q38110962-370D28BB-F694-444C-B26E-4BF6C791DCD5Q38284597-426C9D26-3FCA-457B-BCBF-725EB056104FQ38542060-BF07DCB3-B331-4E6E-AF27-C82B84CD9449Q38787773-FCC04306-1B71-4CE3-8090-F83DA3AB3F72Q38801101-C80B6479-76D6-4018-B9DA-9E547FCE9194Q38998520-818D888F-9161-42B3-8632-1F84A3086557Q39015041-DE26850B-4C26-472C-A8E4-2C367EDF089EQ39252283-425508A4-48E0-4C86-A535-CFCC2C13CF61Q41687834-12605E0F-01F6-4953-94EF-036E7AE282CCQ42113341-101154B7-2409-435C-B83B-071D8780D7EDQ43194164-A0C1F2C8-1653-4EA7-901B-0ECEE8AA591CQ45343074-E3F42AFC-1F31-4CEE-9899-DE89D457592FQ46327752-C7085EAC-7A22-471E-9639-153B8CE56F18Q47797570-BA8D609F-4A77-4112-AC79-4BBA989D71B3Q48320672-3F435AF3-AD75-4EFD-BE36-9F495063DB5A
P2860
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@en
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@nl
type
label
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@en
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@nl
prefLabel
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@en
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@nl
P2093
P356
P1433
P1476
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
@en
P2093
T Hamaguchi
W Takiyama
P304
P356
10.1093/ANNONC/MDH231
P577
2004-06-01T00:00:00Z